All In Biotech

Drug Trial Radar · NCT07527923

First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis

A Two-Part Phase 1, Randomized, Double-Blind, Placebo-Controlled First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN20423 in Adult Healthy Participants and Adult Participants With Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

May 22, 2026

Primary completion

Aug 14, 2028

Study completion Aug 14, 2028

Sponsor

Lead sponsor
Regeneron PharmaceuticalsRegeneron (REGN)
Sponsor type
Industry
First posted
Apr 14, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will test an experimental study medicine called REGN20423 to see how effective it is in healthy participants (in Part A) and participants with atopic dermatitis (eczema) (in Part B). REGN20423 is a study medicine that is only used in clinical studies. REGN20423 has not previously been studied in humans. The study is looking at: * What side effects REGN20423 might cause * How much REGN20423 is in the blood at different times * How well REGN20423 works in adults with atopic dermatitis * Whether the body makes antibodies against REGN20423 * How the body changes after having REGN20423, which can help researchers understand why REGN20423 works better in some people than others * What the best dose of REGN20423 is

Conditions

  • Healthy Volunteer
  • Atopic Dermatitis

Interventions

  • REGN20423Drug

    Administered per the protocol

  • PlaceboOther

    Administered per the protocol

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Occurrence of Treatment Emergent Adverse Events (TEAEs)Time frame: Up to 69 weeks
  2. Severity of TEAEsTime frame: Up to 69 weeks

Locations

9 sites in 2 countries. Site status is shown where the registry gives one.

  • Cahaba Dermatology & Skin Health Center, LLC

    Birmingham, Alabama · Recruiting

  • Arkansas Research Trials

    North Little Rock, Arkansas · Recruiting

  • Alliance Clinical, Focus Clinical Research

    West Hills, California · Recruiting

  • Florida International Research Center

    Miami, Florida · Recruiting

  • Encore Medical Research of Weston LLC

    Weston, Florida · Recruiting

  • Rophe Adult and Pediatric Medicine

    Union City, Georgia · Recruiting

  • National Allergy and Asthma Research, LLC

    North Charleston, South Carolina · Recruiting

  • Texas Dermatology and Laser Specialists

    San Antonio, Texas · Recruiting

  • Center for Clinical Pharmacology University Hospitals Leuven (UZ Leuven)

    Leuven, Vlaams-Brabant, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.